Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Epigenetic Regulation in Cancers
share announcement

Epigenetic Regulation in Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 10 August 2025 | Viewed by 1022

Special Issue Editors

Dr. Sudhir Rai

E-Mail Website
Guest Editor
Cancer Bioinformatic & Biomarker Lab(CBBL)/Fanconi Anemia Signaling Lab(FASL), Department of Quantitative Health Sciences(DQHS)/Cancer Biology Program(CBP), JABSOM/University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI 96813, USA
Interests: transcription factors; cancer metabolism; epigenetics; RNA methylation; pathogenic variants; DDR; Fanconi anemia signaling; DNA-binding proteins
Dr. Seema Kumari

E-Mail Website
Guest Editor
Department of Biochemistry and Bioinformatics, GIS, GITAM (Deemed to Be University), Visakhapatnam 530045, India
Interests: cancer metastasis; anticancer drugs
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Epigenetic modifications play a pivotal role in governing oncogenes, tumor suppressor genes, and the tumor microenvironment, offering a promising avenue for cancer therapy due to their heritable and reversible properties. Various epigenetic modifications, encompassing DNA methylation, histone modifications, microRNAs, and nucleosome remodeling, intricately regulate gene expression in cancer. Dysregulation of the epigenome emerges as a significant contributor to aberrant transcriptional programs in cancer, underscoring the interplay between dysregulated genetic and epigenetic mechanisms. The inherent heterogeneity of cancer necessitates precise personalized therapy utilizing epigenetic drugs, facilitated by high-throughput epigenome mapping technologies. The interconnected cancer hallmarks of metabolic rewiring and epigenetic remodeling exert influence on immune escape and immunosurveillance. Understanding the role of epigenetic factors in hormone therapy response is crucial for overcoming therapeutic resistance. Furthermore, the emerging field of epitranscriptomics, involving RNA chemical modifications, introduces RNA-modifying proteins as potential pharmacological targets and diagnostic markers in the realm of cancer research.

Dr. Sudhir Rai
Dr. Seema Kumari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncogenes
  • tumor suppressor genes
  • tumor microenvironment
  • cancer therapy
  • DNA and histone methylation
  • microRNAs
  • epitranscriptomics
  • RNA modifications
  • modifying proteins

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

15 pages, 1076 KiB  
Review
Epigenetics of Conjunctival Melanoma: Current Knowledge and Future Directions
by Kaylea M. Flick, Hakan Demirci and F. Yesim Demirci
Cancers 2024, 16(21), 3687; https://doi.org/10.3390/cancers16213687 - 31 Oct 2024
Viewed by 708
Abstract
The purpose of this article is to provide a literature review of the epigenetic understanding of conjunctival melanoma (CM), with a primary focus on current gaps in knowledge and future directions in research. CM is a rare aggressive cancer that predominantly affects older [...] Read more.
The purpose of this article is to provide a literature review of the epigenetic understanding of conjunctival melanoma (CM), with a primary focus on current gaps in knowledge and future directions in research. CM is a rare aggressive cancer that predominantly affects older adults. Local recurrences and distant metastases commonly occur in CM patients; however, their prediction and management remain challenging. Hence, there is currently an unmet need for useful biomarkers and more effective treatments to improve the clinical outcomes of these patients. Like other cancers, CM occurrence and prognosis are believed to be influenced by multiple genetic and epigenetic factors that contribute to tumor development/progression/recurrence/spread, immune evasion, and primary/acquired resistance to therapies. Epigenetic alterations may involve changes in chromatin conformation/accessibility, post-translational histone modifications or the use of histone variants, changes in DNA methylation, alterations in levels/functions of short (small) or long non-coding RNAs (ncRNAs), or RNA modifications. While recent years have witnessed a rapid increase in available epigenetic technologies and epigenetic modulation-based treatment options, which has enabled the development/implementation of various epi-drugs in the cancer field, the epigenetic understanding of CM remains limited due to a relatively small number of epigenetic studies published to date. These studies primarily investigated DNA methylation, ncRNA (e.g., miRNA or circRNA) expression, or RNA methylation. While these initial epigenetic investigations have revealed some potential biomarkers and/or therapeutic targets, they had various limitations, and their findings warrant replication in independent and larger studies/samples. In summary, an in-depth understanding of CM epigenetics remains largely incomplete but essential for advancing our molecular knowledge and improving clinical management/outcomes of this aggressive disease. Full article
(This article belongs to the Special Issue Epigenetic Regulation in Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop